Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan

被引：0
作者：
Takahiro Mori
Carolyn J. Crandall
Tomoko Fujii
David A. Ganz
机构：
[1] Chiba University,Department of General Medical Science, Graduate School of Medicine
[2] University of Tsukuba,Health Services Research and Development Center
[3] Eastern Chiba Medical Center,Department of General Internal Medicine
[4] David Geffen School of Medicine at University of California,Division of General Internal Medicine and Health Services Research, Department of Medicine
[5] Los Angeles,Department of Medical Research and Management for Musculoskeletal Pain, 22nd Century Medical and Research Center
[6] University of Tokyo Hospital,Division of Geriatrics, Department of Medicine
[7] Geriatric Research,undefined
[8] Education and Clinical Center and HSR&D Center for the Study of Healthcare Innovation,undefined
[9] Implementation and Policy,undefined
[10] Veterans Affairs Greater Los Angeles Healthcare System,undefined
[11] David Geffen School of Medicine at University of California,undefined
[12] Los Angeles,undefined
[13] Health Unit,undefined
[14] RAND Corporation,undefined
来源：
Archives of Osteoporosis | 2021年 / 16卷
关键词：
Cost-effectiveness analysis; Osteoporosis; Fracture prevention; Zoledronic acid; Denosumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 188 条
[1]  
Cramer JA(2008)Medication compliance and persistence: terminology and definitions Value Health 11 44-47
[2]  
Roy A(2017)Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan Osteoporos Int 28 1733-1744
[3]  
Burrell A(2018)Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension J Bone Miner Res 33 190-198
[4]  
Fairchild CJ(2019)Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 104 1595-1622
[5]  
Fuldeore MJ(2016)Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 31 16-35
[6]  
Ollendorf DA(2019)Can We Pave the Pathway to Fracture Prevention? Ann Intern Med 171 62-63
[7]  
Wong PK(2019)National Institutes of Health Pathways to Prevention Workshop: research gaps for long-term drug therapies for osteoporotic fracture prevention Ann Intern Med 171 51-57
[8]  
Mori T(2017)Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians Ann Intern Med 166 818-839
[9]  
Crandall C(2017)Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA Osteoporos Int 28 585-595
[10]  
Ganz D(2019)The associations of multimorbidity with the sum of annual medical and long-term care expenditures in Japan BMC Geriatr 19 69-322
12345678910